A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia
We thank Professor Robert Gale, the editor-in-chief of the journal of Leukemia, who helped us revising and editing our manuscript. All authors read and approved the final typescript.
Supported by National Natural Science Foundation of China (81470328, 81600130, 81770166, 81720108002), Jiangsu Province Medical Elite Programme (ZDRCA2016022), Project of National Key Clinical Specialty, National Science & Technology Pillar Program (2014BAI09B12), Jiangsu Provincial Special Program of Medical Science (BL2014086 and BE2017751) and National Science and Technology Major Project (2017ZX09304032).
Compliance with ethical standards
The ethics approval of this study was obtained from the Independent Ethics Committee of Nanjing Medical University. The subjects are given written informed consent completing the requirements of the Declaration of Helsinki.
Informed consent was obtained from all individual participants included in the study.
The authors declare that they have no competing interests.
- 8.Yang X, Hoshino A, Taga T, Kunitsu T, Ikeda Y, Yasumi T, Yoshida K, Wada T, Miyake K, Kubota T, Okuno Y, Muramatsu H, Adachi Y, Miyano S, Ogawa S, Kojima S, Kanegane H (2015) A female patient with incomplete hemophagocytic lymphohistiocytosis caused by a heterozygous XIAP mutation associated with non-random X-chromosome inactivation skewed towards the wild-type XIAP allele. J Clin Immunol 35:244–248CrossRefGoogle Scholar